Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.45 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AGER | Q15109 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6316401 | 0.90 | SIGMAR1 (0.48) | SIGMAR1CCR5MAPTPOLBHTR2A | |
| SCHEMBL340327 | 0.82 | HTR2A (0.55) | CCR5HTR2A | |
| SCHEMBL6104472 | 0.78 | SIGMAR1 (0.50) | SIGMAR1CCR5L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL6103397 | 0.77 | CCR5 (0.48) | CCR5KDM4EHTR2A | |
| SCHEMBL6103164 | 0.75 | OPRK1 (0.48) | SIGMAR1CCR5KDM4EPOLBHTR2A | |
| SCHEMBL6309994 | 0.75 | OPRK1 (0.48) | SIGMAR1CCR5KDM4EPOLBHTR2A | |
| SCHEMBL6392559 | 0.73 | CCR5 (0.45) | CCR5KDM4ESMN1; SMN2HTR2A | |
| SCHEMBL342164 | 0.73 | CCR5 (0.56) | CCR5HTR2A | |
| SCHEMBL4354469 | 0.73 | HTR2A (0.64) | CCR5HTR2A | |
| SCHEMBL341489 | 0.72 | HTR2A (0.66) | POLBHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014757-A1 | Azacyclic compounds | ANDERSSON CARL-MAGNUS A (DK) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014757-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | SIGMAR1 295/4885CHRNB2 85/4885CHRNA5 53/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.